Efficacy of Ceritinib After Alectinib for ALK-positive Non-small Cell Lung Cancer

Background: Alectinib is a new standard treatment for treatment-naïve anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC); however, resistance ultimately develops in almost all patients, and data regarding the efficiency of ceritinib for such patients are insufficient. Patie...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:In Vivo
Päätekijät: YOSHIDA, HIRONORI, KIM, YOUNG HAK, OZASA, HIROAKI, SAKAMORI, YUICHI, TSUJI, TAKAHIRO, NOMIZO, TAKASHI, YASUDA, YUTO, YAMAMOTO, TOMOKO, AJIMIZU, HITOMI, HIRAI, TOYOHIRO
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: International Institute of Anticancer Research 2018
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6365750/
https://ncbi.nlm.nih.gov/pubmed/30348720
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21873/invivo.11418
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia